EVE Tregs
Chronic Graft-versus-Host Disease (GvHD), Transplant Rejection
Pre-clinicalActive
Key Facts
Indication
Chronic Graft-versus-Host Disease (GvHD), Transplant Rejection
Phase
Pre-clinical
Status
Active
Company
About Regatta Bio
Regatta Bio is a private, pre-clinical-stage biotech founded in 2021 and based in Boston, MA. The company is pioneering a platform for engineered Treg cell therapies designed to restore immune tolerance in transplantation and autoimmunity. Its pipeline features a de-risked strategy, starting with ex vivo expanded Tregs and advancing to genetically modified CAR-Tregs with enhanced features like IL-2 independence and resistance to standard immunosuppressants. Backed by incubators Eos BioInnovation and Panacea Venture, Regatta is positioned to address significant unmet needs in immune-mediated diseases.
View full company profile